Preclinical and translational immunotherapy work continued to target hard-to-treat cancer biology. Researchers presented preclinical characterization of DMR-001, a long-acting monoclonal antibody targeting mutant calreticulin (CALR-mutant MPNs), laying groundwork for further development in a genomically defined myeloproliferative neoplasm niche. In addition, new data suggested a mechanistic vulnerability for lung cancer immuno-escape, with reports that tumor-associated signaling can rewire fibroblasts to help tumors avoid immune attack. While not yet a direct drug program milestone, the findings broaden the targetable microenvironment map for future combinational strategies.